Virtual Reality; the Effect on Pain Reduction During an External Version.
VIREV
1 other identifier
interventional
85
1 country
1
Brief Summary
SUMMARY Rationale: The use of an external cephalic version (ECV) to rotate the fetus from a non-cephalic to cephalic presentation reduces the rate of caesarean section by approximately two-thirds in term pregnancies with breech presentation. Reducing pain during external cephalic version can contribute to an increase in success rate and consequently reduce the number of cesarean sections. Literature about the effectivity of virtual reality (VR) on acute pain reduction seems promising. Objective: The primary objective of this study is to explore the effect of VR on pain during ECV. Secondary objectives are the rate of successful ECV procedures and to explore tolerability, feasibility and patient satisfaction of VR use. Study design: The study concerns a non-blinded, single centre, randomised controlled trial. Study population: Eligible women who fulfill the inclusion criteria and are scheduled for an external cephalic version in the Zuyderland Medical Centre location Heerlen. Intervention: The study population will be randomly divided into the intervention group (VR-group) or the standard care group. The intervention group can choose for an immersive guided relaxation VR experience or an interactive VR experience during the external version additional to the usual standard care. The participants randomised to the standard care group receive the usual standard care given during external version. Main study parameters/endpoints: The primary outcome is pain measured on a numeric rating scale (NRS). A total of 42 patients have to be included in each group. This means that a total of 84 women will have to be included in the study. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Each participating woman is asked to complete a questionnaire after using VR and the degree of pain perception is questioned on the basis of a 0-10 score (NRS). The study population experiences a very small medical risk when participating to this study. They can experience side-effects of VR for example dizziness or nausea and in rare cases epileptic insults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable pain
Started Nov 2020
Longer than P75 for not_applicable pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 19, 2020
CompletedFirst Submitted
Initial submission to the registry
February 9, 2023
CompletedFirst Posted
Study publicly available on registry
February 24, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedAugust 20, 2024
February 1, 2023
3.1 years
February 9, 2023
August 19, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Change of pain during ECV when using VR (VAS, visual analogue scale)
pain score by VAS visual analogue scale minimum 0-maximum 10 (higher score is a worse outcome).
15 minutes
Secondary Outcomes (2)
Rate of successful ECV procedures
15 minutes
Patient tolerability, feasibility and satisfaction of VR use (questionnaire)
15 minutes
Study Arms (2)
VR group
EXPERIMENTALThe intervention group can choose for an immersive guided relaxation VR experience or an interactive VR experience during the external version Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
Standard care group
NO INTERVENTIONThe participants randomised to the standard care group receive the usual standard care given during external version.Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score.
Interventions
The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
Eligibility Criteria
You may qualify if:
- Written and orally given informed consent
- years and older
- Native Dutch speaker
- Singleton pregnancy in breech position
- Scheduled ECV
You may not qualify if:
- Contraindication for ECV
- Chronic pain patients defined as 'persistent or recurrent pain lasting longer than 3 months' \[16\]. The pain is not due to an obstetrical problem.
- Chronic use of pain medication (opioids)
- Alcohol or drug abuse
- Known car sickness
- Epileptic insults in previous history
- Psychotically seizures in previous history
- Claustrophobic
- Blindness
- History of mental illness
- Patients in strict isolation (MRSA)
- Age \<18 years
- Twin pregnancy
- No native Dutch speaker
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zuyderaland MC
Heerlen, 6419 PC, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
M Wassen, Dr
Zuyderland MC
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Masking Details
- The study population will be randomly divided into the intervention group (VR-group) or the standard care group.
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 9, 2023
First Posted
February 24, 2023
Study Start
November 19, 2020
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
August 20, 2024
Record last verified: 2023-02